In vitro: Imidazopyridine amide (IPA) compounds block Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex. The optimized IPA compound Q203 inhibits the growth of MDR and XDR Mycobacterium tuberculosis clinical isolates in culture broth medium in the low nanomolar range. Q203 is active against the reference strain Mycobacterium tuberculosis H37Rv with MIC50s of 2.7 nM in culture broth medium and 0.28 nM inside macrophages. In vivo: Q203 is efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight. Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Q203 has a bioavailability of 90% and a terminal half-life of 23.4 h. The volume of distribution is moderate (5.27 l per kg body weight), and the systemic clearance is low (4.03 mL/min per kg). After 4 weeks of treatment, reductions of 90%, 99% and 99.9% in M. tuberculosis H37Rv bacterial load is observed in the groups treated with Q203 at 0.4, 2 and 10 mg per kg body weight, respectively.
|Source||Sci Rep (2018). Figure 3. Q203|
|Method||Oxygen consumption activity assay|
|Cell Lines||M. tuberculosis strain|
|Results||However, inhibition of respiratory chain activity by Q203 was incomplete, with ~60% inhibition observed at the highest Q203 concentration tested (10 μM)|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10mM in DMSO|
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
Kang S, et al. J Med Chem. 2014 Jun 26;57(12):5293-305. PMID: 24870926.
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
Pethe K, et al. Nat Med. 2013 Sep;19(9):1157-60. PMID: 23913123.
|Related Anti-infection Products|
Nisin is a bacteriocin produced by a group of Gram-positive bacteria that belongs to Lactococcus and Streptococcus species.
E1210 (APX001A) is the first-in-class inhibitor of the fungal protein Gwt1 (GPI-anchored wall transfer protein 1) in the glycosylphosphatidylinositol (GPI) biosynthesis pathway.
AN2718 is a novel boron-containing small molecule that inhibits an essential protein synthesis enzyme, leucyl-transfer RNA synthetase, or LeuRS.
Tavaborole, also known as AN-2690 is an antifungal agent with activity against Trichophyton species.
Pyronaridine tetraphosphate is a Mannich base anti-malarial with demonstrated efficacy against compound.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.